Detail akcie LENSAR Rg-WI online

Business Summary: LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, LENSAR Inc revenues increased 15% to $42.4M. Net loss increased from $12.7M to $32.8M. Revenues reflect United States segment increase of 17% to $23.1M, Asia (excluding South Korea) segment increase of 69% to $6.5M. Higher net loss reflects Selling, general and administrative increase of 82% to $33.1M (expense), Change in fair value of warrant liabilit increase from $3.8M to $13.6M (expense).